Literature DB >> 28765503

Advance Directives, Hospitalization, and Survival Among Advanced Cancer Patients with Delirium Presenting to the Emergency Department: A Prospective Study.

Ahmed F Elsayem1, Eduardo Bruera2, Alan Valentine3, Carla L Warneke4, Geri L Wood5, Sai-Ching J Yeung6, Valda D Page6, Julio Silvestre6, Patricia A Brock6, Knox H Todd6.   

Abstract

BACKGROUND: To improve the management of advanced cancer patients with delirium in an emergency department (ED) setting, we compared outcomes between patients with delirium positively diagnosed by both the Confusion Assessment Method (CAM) and Memorial Delirium Assessment Scale (MDAS), or group A (n = 22); by the MDAS only, or group B (n = 22); and by neither CAM nor MDAS, or group C (n = 199).
MATERIALS AND METHODS: In an oncologic ED, we assessed 243 randomly selected advanced cancer patients for delirium using the CAM and the MDAS and for presence of advance directives. Outcomes extracted from patients' medical records included hospital and intensive care unit admission rate and overall survival (OS).
RESULTS: Hospitalization rates were 82%, 77%, and 49% for groups A, B, and C, respectively (p = .0013). Intensive care unit rates were 18%, 14%, and 2% for groups A, B, and C, respectively (p = .0004). Percentages with advance directives were 52%, 27%, and 43% for groups A, B, and C, respectively (p = .2247). Median OS was 1.23 months (95% confidence interval [CI] 0.46-3.55) for group A, 4.70 months (95% CI 0.89-7.85) for group B, and 10.45 months (95% CI 7.46-14.82) for group C. Overall survival did not differ significantly between groups A and B (p = .6392), but OS in group C exceeded those of the other groups (p < .0001 each).
CONCLUSION: Delirium assessed by either CAM or MDAS was associated with worse survival and more hospitalization in patients with advanced cancer in an oncologic ED. Many advanced cancer patients with delirium in ED lack advance directives. Delirium should be assessed regularly and should trigger discussion of goals of care and advance directives. IMPLICATIONS FOR PRACTICE: Delirium is a devastating condition among advanced cancer patients. Early diagnosis in the emergency department (ED) should improve management of this life-threatening condition. However, delirium is frequently missed by ED clinicians, and the outcome of patients with delirium is unknown. This study finds that delirium assessed by the Confusion Assessment Method or the Memorial Delirium Assessment Scale is associated with poor survival and more hospitalization among advanced cancer patients visiting the ED of a major cancer center, many of whom lack advance directives. Therefore, delirium in ED patients with cancer should trigger discussion about advance directives. © AlphaMed Press 2017.

Entities:  

Keywords:  Advance directives; Cancer; Delirium; Emergency; Survival

Mesh:

Year:  2017        PMID: 28765503      PMCID: PMC5679826          DOI: 10.1634/theoncologist.2017-0115

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  31 in total

1.  Prognostic value and risk factors of delirium in emergency patients with decompensated heart failure.

Authors:  Miguel Alberto Rizzi; Olga Herminia Torres Bonafonte; Aitor Alquezar; Sergio Herrera Mateo; Pascual Piñera; Mireia Puig; Salvador Benito; Domingo Ruiz
Journal:  J Am Med Dir Assoc       Date:  2015-07-11       Impact factor: 4.669

2.  Patients with delirium and advanced solid cancer in the emergency department: A challenge for the emergency practitioner, oncologist, and intensivist.

Authors:  François Vincent; Ida Pavese; Joseph Gligorov; Emmanuelle Zamparini; Caroline Bornstain
Journal:  Cancer       Date:  2016-11-14       Impact factor: 6.860

3.  Cancer patients with delirium in the emergency department: A frequent and distressing problem that calls for better assessment.

Authors:  Peter G Lawlor
Journal:  Cancer       Date:  2016-07-25       Impact factor: 6.860

4.  Delirium in the emergency department: an independent predictor of death within 6 months.

Authors:  Jin H Han; Ayumi Shintani; Svetlana Eden; Alessandro Morandi; Laurence M Solberg; John Schnelle; Robert S Dittus; Alan B Storrow; E Wesley Ely
Journal:  Ann Emerg Med       Date:  2010-04-03       Impact factor: 5.721

5.  Survival prediction for advanced cancer patients in the real world: A comparison of the Palliative Prognostic Score, Delirium-Palliative Prognostic Score, Palliative Prognostic Index and modified Prognosis in Palliative Care Study predictor model.

Authors:  Mika Baba; Isseki Maeda; Tatsuya Morita; Satoshi Inoue; Masayuki Ikenaga; Yoshihisa Matsumoto; Ryuichi Sekine; Takashi Yamaguchi; Takeshi Hirohashi; Tsukasa Tajima; Ryohei Tatara; Hiroaki Watanabe; Hiroyuki Otani; Chizuko Takigawa; Yoshinobu Matsuda; Hiroka Nagaoka; Masanori Mori; Yo Tei; Shuji Hiramoto; Akihiko Suga; Hiroya Kinoshita
Journal:  Eur J Cancer       Date:  2015-06-11       Impact factor: 9.162

Review 6.  Evidence-based treatment of delirium in patients with cancer.

Authors:  William Breitbart; Yesne Alici
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

7.  Barriers to goals of care discussions with seriously ill hospitalized patients and their families: a multicenter survey of clinicians.

Authors:  John J You; James Downar; Robert A Fowler; François Lamontagne; Irene W Y Ma; Dev Jayaraman; Jennifer Kryworuchko; Patricia H Strachan; Roy Ilan; Aman P Nijjar; John Neary; John Shik; Kevin Brazil; Amen Patel; Kim Wiebe; Martin Albert; Anita Palepu; Elysée Nouvet; Amanda Roze des Ordons; Nishan Sharma; Amane Abdul-Razzak; Xuran Jiang; Andrew Day; Daren K Heyland
Journal:  JAMA Intern Med       Date:  2015-04       Impact factor: 21.873

8.  Delirium frequency among advanced cancer patients presenting to an emergency department: A prospective, randomized, observational study.

Authors:  Ahmed F Elsayem; Eduardo Bruera; Alan D Valentine; Carla L Warneke; Sai-Ching J Yeung; Valda D Page; Geri L Wood; Julio Silvestre; Holly M Holmes; Patricia A Brock; Knox H Todd
Journal:  Cancer       Date:  2016-07-25       Impact factor: 6.860

9.  A Patient-Reported Outcome Instrument to Facilitate Timing of End-of-Life Discussions among Patients with Advanced Cancers.

Authors:  Stuart L Goldberg; Andrew L Pecora; Jose Contreras; Katherine E DeMarco; Dhakshila Paramanathan; Victoria DeVincenzo; Eric Schultz; Kelly Choi
Journal:  J Palliat Med       Date:  2016-06-27       Impact factor: 2.947

10.  Characteristics, findings, and outcomes of palliative care inpatient consultations at a comprehensive cancer center.

Authors:  Fadi Braiteh; Badi El Osta; J Lynn Palmer; Suresh K Reddy; Eduardo Bruera
Journal:  J Palliat Med       Date:  2007-08       Impact factor: 2.947

View more
  4 in total

1.  Patient Perspectives on Advance Care Planning via a Patient Portal.

Authors:  Sarah R Jordan; Adreanne Brungardt; Phoutdavone Phimphasone-Brady; Hillary D Lum
Journal:  Am J Hosp Palliat Care       Date:  2019-02-25       Impact factor: 2.500

2.  Analysis of Diagnoses, Symptoms, Medications, and Admissions Among Patients With Cancer Presenting to Emergency Departments.

Authors:  Jeffrey M Caterino; David Adler; Danielle D Durham; Sai-Ching Jim Yeung; Matthew F Hudson; Aveh Bastani; Steven L Bernstein; Christopher W Baugh; Christopher J Coyne; Corita R Grudzen; Daniel J Henning; Adam Klotz; Troy E Madsen; Daniel J Pallin; Cielito C Reyes-Gibby; Juan Felipe Rico; Richard J Ryan; Nathan I Shapiro; Robert Swor; Arvind Venkat; Jason Wilson; Charles R Thomas; Jason J Bischof; Gary H Lyman
Journal:  JAMA Netw Open       Date:  2019-03-01

3.  Oncologic emergency in patients with skeletal metastasis of unknown primary.

Authors:  Tomoaki Torigoe; Jungo Imanishi; Yasuo Yazawa; Tadaaki Koyama; Yuho Kadono; Hiromi Oda; Kazuo Saita
Journal:  Acute Med Surg       Date:  2021-02-04

4.  Treatment Limitation Decisions in Critically Ill Patients With a Malignancy on the Intensive Care Unit.

Authors:  Esther N van der Zee; Jelle L Epker; Jan Bakker; Dominique D Benoit; Erwin J O Kompanje
Journal:  J Intensive Care Med       Date:  2020-08-13       Impact factor: 3.510

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.